Long-term Follow-up of Third-generation Anti-CD30 CAR T-cell Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicenter, Phase I/II Trial.
Clin Cancer ResOct 1, 2026
Xiangmin Wang, Qing Zhang, Dongmei Yan et al.
✦ AI-curated · Sources linked
In 30 seconds
This single-arm, multicenter, phase I/II trial evaluated long-term outcomes of third-generation anti-CD30 CAR T-cell therapy in 44 patients with relapsed/refractory CD30+ lymphoma. The study found a complete response (CR) rate of 52.3% and an overall response rate (ORR) of 95.5%. Three-year overall survival (OS) and progression-free survival (PFS) rates were 79% and 74.2%, respectively.
Key findings
- Complete response (CR) rate was 52.3% among patients receiving CAR T therapy.
- Overall response rate (ORR) reached 95.5% in the study population.
- Three-year overall survival (OS) rate was 79% with a 95% confidence interval of 66.1%-91.9%.
- Patients receiving auto-HSCT after CAR T had a CR rate of 75% compared to 45% for CAR T alone.
Why it matters
The findings highlight the potential of third-generation anti-CD30 CAR T-cell therapy as an effective treatment for relapsed/refractory CD30+ lymphoma, particularly when followed by autologous hematopoietic stem cell transplantation, which may enhance patient outcomes.